β-Alanine methyl ester hydrochloride 3196-73-4, C4H10ClNO2, molecular weight 139.58 g/mol, is supplied as a white to off-white crystalline solid with assay typically not less than 98.0% by non-aqueous titration. The product functions as a protected β-amino acid synthon in downstream synthesis rather than as a final formulation component. Industrial handling requires moisture-controlled dosing because the hydrochloride salt equilibrates with ambient humidity above 45% RH and may agglomerate during drum discharge. The applications below are restricted to documented downstream chemistries in which the methyl ester salt or its immediate N-acyl or amide derivatives are consumed in defined unit operations.

In solution-phase peptide coupling under cGMP intermediate manufacture, the hydrochloride salt is first suspended in anhydrous dimethylformamide or dichloromethane and treated with N-methylmorpholine or diisopropylethylamine at 0–5°C. The liberated methyl 3-aminopropanoate is immediately acylated by an N-protected amino acid or peptide fragment to form the β-alanyl amide bond. Pilot-scale and commercial batch records typically specify 1.00 mol of β-alanine methyl ester hydrochloride to 1.00–1.10 mol of the N-protected carboxyl component, 1.05–1.20 mol of coupling reagent, and 2.0–2.5 mol of tertiary amine base. Coupling is conducted in glass-lined or Hastelloy C-22 reactors with jacket temperature control, holding the reaction mass below 8°C during the initial 15–20 min of reagent mixing. Failure to maintain this window at pH above 9.0 accelerates saponification of the methyl ester, generating β-alanine hydrochloride and reducing isolated yield by 5–12% in affected batches. Workup involves dilution with ethyl acetate, sequential washes with 5–10 wt% citric acid, 8–10 wt% sodium bicarbonate, and water, followed by drying over magnesium sulfate and vacuum distillation at jacket temperature not exceeding 40°C. Crystallization from ethyl acetate/heptane produces an N-protected β-alanyl amino acid ester with residual solvent levels controlled under ICH Q3C. For API intermediate supply, the process must comply with ICH Q7 and EU GMP Part II; impurity characterization is governed by ICH Q3A. Terminal product types include N-protected β-alanyl amino acid esters, dipeptide fragment intermediates, and protected β-alanine derivatives for downstream assembly of peptide-based active pharmaceutical ingredients.

What Process Controls Stabilize the Methyl Ester Salt in β-Alanyl Dipeptide Synthesis?

β-Alanyl-L-histidine and related dipeptides are assembled by coupling the methyl ester hydrochloride to histidine derivatives bearing trityl or Boc protection on the imidazole nitrogen. The salt is charged at 1.00 mol relative to 1.05–1.15 mol of protected histidine, with 1.10–1.25 mol of coupling reagent and 2.2–2.5 mol of base. The reaction is run in anhydrous dimethylformamide at −5°C to +4°C for 2–4 h, then slowly warmed to 20–22°C and monitored by high-performance liquid chromatography until the protected β-alanyl histidine intermediate exceeds 98% area purity. Karl Fischer titration of the solvent before charging is maintained below 500 ppm water; higher moisture levels divert the activated carboxyl component to hydrolysis and reduce coupling yield by 10–15%. Following coupling, deprotection is performed with trifluoroacetic acid/triisopropylsilane/water 95:2.5:2.5 under inert atmosphere, followed by precipitation in cold methyl tert-butyl ether and ion-exchange purification. Compliance for peptide ingredients intended for cosmetic or dietary raw material manufacture follows ISO 22716:2007 and EU Regulation (EC) No 1223/2009, with REACH (EC) No 1907/2006 registration for the chemical intermediate. Terminal product types include carnosine, β-alanyl-L-histidine, and modified β-alanyl dipeptides used as anti-glycation actives and functional peptide raw materials.

Solid-phase assembly of β-peptide oligomers using the methyl ester hydrochloride does not directly couple the salt to resin; instead, the compound is first N-Fmoc-protected under Schotten-Baumann conditions to yield N-Fmoc-β-alanine methyl ester, which is then saponified to the resin-loadable acid. Coupling on aminomethyl polystyrene or 2-chlorotrityl resin is performed with 3–5 equivalents of N-Fmoc-β-alanine relative to resin free amine, 3–5 equivalents of N,N′-diisopropylcarbodiimide, and 3–5 equivalents of Oxyma Pure in dimethylformamide. Resin substitution is maintained at 0.3–0.8 mmol/g; loadings above 1.0 mmol/g increase interchain aggregation and reduce the coupling efficiency of subsequent β-peptide residues. Iterative Fmoc deprotection with 20% piperidine in dimethylformamide, capping with acetic anhydride/pyridine, and final cleavage with trifluoroacetic acid/triisopropylsilane/water 95:2.5:2.5 yield the crude β-peptide oligomer. The process is monitored by Kaiser test and liquid chromatography–mass spectrometry; batch-to-batch variance in resin swelling is controlled by pre-swelling in dichloromethane for 30 min before the first coupling. Quality systems for research and industrial peptide manufacturing follow ISO 9001:2015, and pharmaceutical development batches reference ICH Q11 for drug substance development. Terminal product types include β-peptide oligomers, foldamer screening compounds, and amide-linked peptidomimetic intermediates.

Acrylate Monomer Derivatization and Radical Copolymerization Parameters

N-Acryloyl-β-alanine methyl ester is prepared by reacting the hydrochloride salt with acryloyl chloride in anhydrous dichloromethane or toluene at −5°C to 0°C, using 2.0–2.5 mol of triethylamine or polymeric amine scavenger per mol of salt. The washed organic phase is filtered through silica and immediately stabilized with 100–300 ppm 4-methoxyphenol to inhibit spontaneous polymerization during storage and shipping. The isolated vinyl monomer is copolymerized with methyl methacrylate, butyl acrylate, or hydroxyethyl acrylate at comonomer feed ratios of 2–10 mol%, with azobisisobutyronitrile initiator at 0.1–0.5 mol% relative to total monomer in solution polymerization at 65–75°C. Oxygen content in the reactor headspace is reduced to below 50 ppm before heating; residual oxygen retards the radical chain and causes molecular weight distribution broadening. Tensile properties of cast films are measured under ASTM D638-14, and liquid-resin viscosity is determined under ISO 2555. Residual monomer in devolatilized copolymer is controlled by customer specification, typically below 100 ppm after wiped-film evaporation. Industrial monomer and polymer manufacture is conducted under REACH (EC) No 1907/2006 registration, CLP (EC) No 1272/2008 classification, and ISO 9001:2015 quality management. Terminal product types include pressure-sensitive adhesive films, crosslinkable hydrogel coatings, and reactive oligomers for UV-curable laminating adhesives.

Amide Bond Formation Extends the Ester Hydrochloride to 3-Aminopropionamide Fine Chemical Intermediates

Reaction of β-alanine methyl ester hydrochloride with primary aliphatic amines or ammonia produces 3-aminopropionamide intermediates, which serve as stable amine-functionalized building blocks for further heterocycle or peptide bond formation. A typical charge ratio is 1.00 mol of the ester hydrochloride to 1.05–1.20 mol of amine, with 1.10–1.30 mol of sodium methoxide or triethylamine in methanol at 15–25°C. The reaction is maintained for 12–24 h in a pressure-rated vessel when methylamine or ammonia gas is used; liberation of the free base before amide attack minimizes ester hydrolysis to β-alanine. Workup includes neutralization with dilute hydrochloric acid, filtration of sodium chloride or triethylamine hydrochloride, and vacuum distillation or crystallization. Compliance for fine chemical intermediates follows ISO 9001:2015 quality management, with residual solvent testing under ICH Q3C when the amide is destined for pharmaceutical projects. Terminal product types include N-alkyl 3-aminopropionamides and protected amine intermediates used in medicinal chemistry libraries and as intermediates for saturated heterocyclic scaffolds.